


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CVGENG.008CP1	APPLICATION NO. 10/849,480
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Stegmann, et al.	
		FILING DATE August 27, 2003	GROUP Unknown



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)	

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
BCI	Hendel, et al. "Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion," <i>Circulation</i> , Vol. 101, pp. 118-121, 2000.
	Laham, et al. "Subxyphoid Access of the Normal Pericardium: A Novel Drug Delivery Technique," <i>Catheterization and Cardiovascular Interventions</i> , Vol. 47, pp. 109-111, 1999.
	Laham, et al. "Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery, Results of a Phase I Randomized, Double-Blind, Placebo-Controlled Trial," <i>Circulation</i> , Vol. 100, pp. 1865-1871, 1999.
	Rosengart, et al. "Angiogenesis Gene Therapy, Phase I Assessment of Direct Intramyocardial Administration of an Adenovirus Vector Expressing VEGF121 cDNA to Individuals with Clinically Significant Severe Coronary Artery Disease," <i>Circulation</i> , Vol. 100, pp. 468-474, 1999.
	Stegmann, et al. "First Angiogenic Treatment of Coronary heart Disease by FGF-1: Long-Term Results After 3 years," <i>Cardiac and Vascular Regeneration</i> , Vol. 1, No. 1, pp. 5-10, March, 2000.
	Symes, et al. "Gene Therapy with Vascular Endothelial Growth Factor for Inoperable Coronary Artery Disease," <i>Annals of Thoracic Surgery</i> , Vol. 68, pp. 830-837, 1999.
	Udelson, et al. "Therapeutic Angiogenesis with Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients with Severe Symptomatic Chronic Coronary Artery Disease," <i>Circulation</i> , Vol. 102, pp. 1605-1610, 2000.
	Waxman, et al. "Persistent Primary Coronary Dilation Induced by Transatrial Delivery of Nitroglycerin into the Pericardial Space: A Novel Approach for Local Cardiac Drug Delivery," <i>Journal of the American College of Cardiology</i> , Vol. 33, No. 7, pp. 2073-2077, June, 1999.

H:\DOCS\CSC\CSC-5865.DOC
100803

EXAMINER <i>Dougan L</i>	DATE CONSIDERED <i>06/14/2005</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	